Lundbeck Canada Inc. is a research-base pharmaceutical company, specializing in the development of new therapies for psychiatric and neurological diseases.  Cipralex® is one of the new treatment options we recently introduced in Canada, and we are committed to bringing future innovations in the treatment of central nervous system disorders.

Psychiatric and neurological disorders are complex.  Our goal is simple – to improve the quality of life for patients and their caregivers, and the treatment options for their dedicated healthcare professionals.

 

For more information, log onto their website at www.lundbeck.ca